Craft

Evotec

Stock Price

€7.2

2024-10-29

Market Capitalization

€1.3 B

2024-10-29

Revenue

€788.4 M

FY, 2025

Evotec Summary

Company Summary

Overview
Evotec is a biotechnology company that provides drug discovery and development services. It focuses on oncology, autoimmune and infectious, cardiometabolic disorders, and fibrotic and respiratory diseases. The company caters to the pharmaceutical, biotech, foundations, and government agencies.
Type
Public
Status
Active
Founded
1993
HQ
Hamburg, DE | view all locations
Website
https://www.evotec.com/en/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • Craig Johnstone

    Craig Johnstone, Chief Operating Officer

  • Cord Dohrmann

    Cord Dohrmann, Chief Scientific Officer

  • Volker Braun

    Volker Braun, Head of Global Investor Relations & ESG

  • Laetitia Rouxel

    Laetitia Rouxel, Chief Financial Officer

Operating MetricsView all

Scientists and Researchers

4.2K
4.3%

FY, 2023

Projects

110

FY, 2023

New Customers

298
8.3%

FY, 2023

LocationsView all

13 locations detected

  • Hamburg, HH HQ

    Germany

    Essener Bogen 7

  • Branford, CT

    United States

    33 Business Park Drive #6

  • Redmond, WA

    United States

    22857 NE Marketplace Drive

  • Lyon, Auvergne-Rhône-Alpes

    France

    40 Avenue Tony Garnier

  • Toulouse, Occitanie

    France

    195, route d‘Espagne

  • Göttingen, NDS

    Germany

    Marie-Curie-Str. 7

and 7 others

Evotec Financials

Summary Financials

Revenue (Q1, 2026)
€156.6M
Gross profit (Q1, 2026)
€10.9M
Net income (Q1, 2026)
(€121.9M)
Cash (Q1, 2026)
€387.9M
EBIT (Q1, 2026)
(€121.6M)
Enterprise value
$1.3B

Footer menu